Investigational Drug Details
| Drug ID: | D337 |
| Drug Name: | Simtuzumab |
| Synonyms: | SIM, GS-6624; GS-6624; Simtuzumab |
| Type: | Biological drug |
| DrugBank ID: | DB12152 |
| DrugBank Description: | Simtuzumab has been used in trials studying the treatment and basic science of Myelofibrosis, Pancreatic Cancer, Colorectal Cancer, and Idiopathic Pulmonary Fibrosis. |
| PubChem ID: | -- |
| CasNo: | 1318075-13-6 |
| Repositioning for NAFLD: | No |
| SMILES: | -- |
| InChiKey: | -- |
| Molecular Weight: | -- |
| DrugBank Targets: | -- |
| DrugBank MoA: | -- |
| DrugBank Pharmacology: | -- |
| DrugBank Indication: | -- |
| Targets: | LOXL2; antibody |
| Therapeutic Category: | Anti-fibrosis; Anticancer agent; Immunomodulator; |
| Clinical Trial Progress: | Phase 2 terminated (In two phase 2b trials of patients with bridging fibrosis or compensated cirrhosis associated with nonalcoholic steatohepatitis, simtuzumab was ineffective in decreasing hepatic collagen content or hepatic venous pressure gradient, respectively. Clinicaltrials.govNCT01672866 and NCT01672879.) |
| Latest Progress: | Failed in clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0285 | NCT02466516 | Phase 2 | Completed | Has Results | June 8, 2015 | June 26, 2019 | Details |
| L0347 | NCT01672866 | Phase 2 | Terminated | Has Results | December 5, 2012 | March 27, 2019 | Details |
| L0367 | NCT01672879 | Phase 2 | Terminated | Has Results | October 29, 2012 | March 27, 2019 | Details |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S03 | Anti-fibrosis | fibrosis | Angiotensin Receptor Blocker (ARB); CCR2/CCR5 antagonist; Thyroid receptor β agonist; PEGylated human FGF21 analogue; Monoclonal antibody to lysyl oxidase-like 2 (LOXL2); Galectin-3 inhibitor; FGF19 variant | Losartan; Cenicriviroc; VK-2809; MGL-3196; Pegbelfermin; Simtuzumab; GR-MD-02; NGM282 | Details |
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A01666 | 34662449 | Hepatology | Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis. | Details |
| A05119 | 33368954 | Diabetes Obes Metab | Pioglitazone and bariatric surgery are the most effective treatments for non-alcoholic steatohepatitis: A hierarchical network meta-analysis. | Details |
| A05306 | 33307033 | Gastroenterology | The Association of Histologic and Noninvasive Tests With Adverse Clinical and Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis. | Details |
| A11213 | 30993748 | Hepatology | The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials. | Details |
| A13414 | 29990488 | Gastroenterology | Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis. | Details |
| A14506 | 29377462 | Liver Int | Improvement of hepatic fibrosis and patient-reported outcomes in non-alcoholic steatohepatitis treated with selonsertib. | Details |
| A15013 | 29128056 | Clin Liver Dis | Emerging Treatments for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. | Details |
| A15468 | 28892558 | Hepatology | The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial. | Details |
| A17704 | 27646933 | Gut | Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease. | Details |
| A18671 | 27003143 | Dig Dis Sci | Novel Pharmacotherapy Options for NASH. | Details |
| A20204 | 26085906 | World J Hepatol | Non-alcoholic fatty liver disease in 2015. | Details |
| A30654 | 32039401 | JHEP Rep | Methylation signatures in peripheral blood are associated with marked age acceleration and disease progression in patients with primary sclerosing cholangitis. | Details |
| A44317 | 29055391 | Med Hypotheses | A quick overview to the early phase clinical trials of Simtuzumab®: Are we loosing the most promising anti-fibrotic product? | Details |
| A47953 | 28480218 | Biomed Res Int | Magnetic Resonance Elastography Shear Wave Velocity Correlates with Liver Fibrosis and Hepatic Venous Pressure Gradient in Adults with Advanced Liver Disease. | Details |
| A51326 | 35601801 | Therap Adv Gastroenterol | Changes in the gut microbiome associated with liver stiffness improvement in nonalcoholic steatohepatitis. | Details |